Computational frameworks for modelling cancer across scales
Clinical and Translational Discovery · 2025-12 · 5 (6)
DOI: 10.1002/ctd2.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Discovery, online erschienen am 03.11.2025. Verfasst von Celine Desoyer und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Cancer progression is a non‐linear, multiscale process driven by the interaction of molecular, cellular and tissue systems, which ultimately leads to tumour growth, invasion and metastasis. Understanding and predicting these dynamics is essential for improving diagnostics and personalising therapy. Mathematical and computational modelling has become central to this effort, enabling in silico simulations of progression and treatment response.
Methods
This survey outlines computational frameworks for modelling cancer across biological scales, incorporating mathematical formalisms and algorithmic paradigms. These frameworks include: ordinary and partial differential equation models of growth, angiogenesis and invasion; agent‐based and hybrid multiscale approaches that capture heterogeneity and microenvironmental feedback; emerging digital twin platforms that integrate mechanistic and data‐driven modelling for patient‐specific predictions. Recent advances in artificial intelligence (AI), such as graph neural networks, transformer‐based architectures and multimodal data fusion, enhance these frameworks by combining interpretability with predictive power through mechanistic learning pipelines.
Results
Based on these advances, the survey presents a conceptual roadmap for multiscale cancer modelling. This roadmap offers a structured workflow that begins with defining the biological question and modelling scale and continues through selecting appropriate paradigms, calibrating and validating models with experimental or clinical data and integrating multimodal information into individualised simulations. The long‐term goal is to develop digital twins of cancer that can personalise and optimise therapy and ultimately guide clinical decisions. These models will capture processes ranging from single‐cell dynamics and cancer progression to angiogenesis, tumour evolution and treatment response. To achieve this vision, we need advances in parameter calibration, multimodal dataset integration and cross‐scale model validation.
Conclusion
Computational oncology bridges the gap between biological mechanisms and predictive modelling, offering a framework for reproducible, data‐driven precision medicine. The convergence of mechanistic modelling, AI‐assisted inference and digital twin technologies establishes a continuum for translating research into real‐time, patient‐specific decision support in oncology. Highlights Provides an integrative overview of computational frameworks for modelling cancer across biological scales. Illustrates the characteristics, advantages, and limitations of ODE/PDE, agent‐based, hybrid multiscale, and integrative translational models. Highlights how these paradigms collectively bridge mechanistic understanding with clinical translation. Presents a conceptual roadmap linking modelling methodologies to precision oncology applications.
Zitieren
APA
Desoyer, C., Loibner, D., Brislinger, D., & Baumgartner, C. (2025). Computational frameworks for modelling cancer across scales. Clinical and Translational Discovery, 5(6). https://doi.org/10.1002/ctd2.70093
Vancouver
Desoyer C, Loibner D, Brislinger D, Baumgartner C. Computational frameworks for modelling cancer across scales. Clinical and Translational Discovery. 2025;5(6). doi:10.1002/ctd2.70093
BibTeX
@article{Desoyer2025,
author = {Desoyer, Celine and Loibner, Daniel and Brislinger, Dagmar and Baumgartner, Christian},
title = {Computational frameworks for modelling cancer across scales},
journal = {Clinical and Translational Discovery},
year = {2025},
volume = {5},
number = {6},
doi = {10.1002/ctd2.70093}
}
EUVIMED